Pharmaceuticals | |
Toxicological Studies of 212Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial | |
Diane E. Milenic2  Alfredo A. Molinolo3  Mar S. Solivella3  Eileen Banaga1  Julien Torgue1  Sarah Besnainou2  Martin W. Brechbiel2  Kwamena E. Baidoo2  | |
[1] Areva Med LLC, 4800 Hampden Lane, Suite 200, Bethesda, MD 20817, USA; E-Mails:;Radioimmune & Inorganic Chemistry Section, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; E-Mails:;Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA; E-Mails: | |
关键词: Pb-212; FDA toxicity study; radioimmunotherapy; targeted alpha-radiation; | |
DOI : 10.3390/ph8030416 | |
来源: mdpi | |
【 摘 要 】
Faced with the novelty of a 212Pb-labeled monoclonal antibody (mAb) for clinical translation, concerns were expressed by the Food and Drug Administration (FDA) regarding 212Pb prematurely released from the mAb-chelate conjugate. The objective of this study was to simulate the worst case scenario of such a failure. Groups of Balb/c mice (
【 授权许可】
CC BY
© 2015 by the authors; licensee MDPI, Basel, Switzerland.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202003190008762ZK.pdf | 2811KB | download |